Treatment of Indolent Systemic Mastocytosis With PA101

Summary

This is a randomized, placebo- and active-controlled, 2-period crossover, 2 cohort study in adult patients with indolent systemic mastocytosis (ISM). The purpose of the study is to determine the efficacy and safety profile of PA101 delivered via eFlow high efficiency nebulizer in patients with ISM who are symptomatic despite using standard treatments.

Timeline

Start

2015-06

Primary completion

2016-03

Completion

2016-06

Drugs

Indications